<DOC>
	<DOCNO>NCT02788058</DOCNO>
	<brief_summary>To evaluate efficacy toxicity patient treat hypofractionated radiotherapy limit metastatic NSCLC harbor sensitize EGFR mutation first line TKI therapy . An exploratory biomarker analysis blood tumor sample also plan .</brief_summary>
	<brief_title>A Study Hypofractionated Radiotherapy Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy</brief_title>
	<detailed_description>Rational : After inductive TKI therapy NSCLC sensitize EGFR mutation , residual lesion might source subsequent disease progression , define acquire resistance TKI . Two reason use explain formation residual lesion：1）there subgroup cancer cell sensitive TKI therapy tumor heterogeneity , like de novo T790M mutation ; 2 ) cancer cell keep static state beginning treatment , develop acquire resistance TKI therapy long-term drug pressure continue re-proliferation . From point view , elimination residual lesion provide chance reduce slow possibility develop resistance TKI . Objective : To evaluate efficacy toxicity patient treat hypofractionated radiotherapy limit metastatic NSCLC harbor sensitize EGFR mutation first line TKI therapy . An exploratory biomarker analysis blood tumor sample also plan .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Newly diagnose metastatic lung adenocarcinoma harbor sensitize EGFR mutation ( L858R , exon 19 deletion ) , become oligometastatic disease 3 month TKI , evaluate PET/CT scan , brain MRI , abdomen ultrasound ( ≤6 discrete lesion disease , exclusive brain metastasis , ≤3 lesion liver , ≤3 lesion lung ) ; All sit disease must amenable definitive RT ; An intrathoracic lymph nodal station consider 1 discrete lesion , accord IASLC lymph nodal station map ; Age 18 year old ; ECOG Performance Status 02 ; Adequate bone marrow , liver renal function , specify : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ; Hemoglobin ≥ 8 g/dL ; Platelets ≥ 100 x 109/L ; Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; AST ALT ≤ 2.5 x ULN ≤ 5 x ULN liver metastases present ; Serum creatinine ≤ 1.5 x upper limit normal creatinine clearance ≥ 60ml/min patient creatinine level institutional normal ; For woman childbearing potential , negative pregnancy test within 14 day prior start treatment ; Men woman childbearing age must willing use effective contraception treatment least 3 month thereafter ; Patients family sign informed consent ; Received chemotherapy TKI therapy ; Brain parenchyma leptomeningeal disease ; Any site disease amenable definitive RT ; Concurrent malignancy nonmelanoma skin cancer require active ongoing treatment ; Any medical comorbidities would preclude radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hypofractionated Radiotherapy</keyword>
	<keyword>EGFR Positive</keyword>
	<keyword>Lung Adenocarcinoma</keyword>
	<keyword>Limited Metastases</keyword>
</DOC>